Combined inactivated bacterial vaccine (Td + acellular pertussis)
ATC code: J07AJ52 (Tdap)
Contains tetanus toxoid, reduced-dose diphtheria toxoid (d, adult), and 3-5 acellular pertussis components (pertactin, FHA, pertussis toxoid, fimbriae). Induces IgG against all three pathogens. Active maternal immunization at 27-36 weeks is the most effective strategy to protect newborns from pertussis.
First line
Active maternal immunization against pertussis. Per CDC ACIP 2023, 2023, SEGO 2023 – every pregnancy at 27-36 weeks, optimally 27-30. Reduces pertussis in infants <3 months by 78-91% (NEJM 2017). Tetanus/diphtheria booster every 10 years.
First line
Tdap during breastfeeding. Fully compatible. If missed in pregnancy – vaccinate immediately postpartum. Antibodies protect the infant via milk.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Recommended at 27-36 weeks each pregnancy. Safe.
Fully compatible. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Tdap – tetanus, diphtheria, acellular pertussis vaccine is evaluated for the following indications with varying evidence strength: Maternal vaccination (evidence tier A), Vaccination during breastfeeding (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Tdap – tetanus, diphtheria, acellular pertussis vaccine (≥ 1 in 100): Injection-site pain/swelling (60%), Fatigue, Headache, Myalgia, Low-grade fever. See the Safety section for uncommon and serious reactions.
FDA category B. Recommended at 27-36 weeks each pregnancy. Safe.
Fully compatible. Hale L1.
Tdap – tetanus, diphtheria, acellular pertussis vaccine is contraindicated in: Anaphylaxis to previous dose or components; Encephalopathy within 7 days of prior pertussis-containing vaccine; Acute febrile illness (defer). Full list in the Safety section.